Persistently high levels of hepatitis B virus (HBV) DNA in patients with chronic HBV infection
have been clearly implicated in an increased risk of liver cirrhosis and hepatocellular …

Introduction: At present, two strategies exist for the treatment of chronic hepatitis B (CHB): i)
standard or pegylated interferon alpha (IFN) with mainly immune modulatory effects; and ii) …

Despite the introduction of effective vaccination programs in a substantial number of
countries, it is anticipated that in the coming decades many hepatitis B virus (HBV)-infected …

Chronic hepatitis B virus (HBV) infection is a dynamic state in which HBV replication is the
key driving force of disease progression, resulting in the development of hepatic …

With great interest we read the new EASL clinical practice guidelines for the management of
chronic hepatitis B. First, we would, like to complement the authors with these concise and …

Hepatitis B virus (HBV) infection is the leading cause of chronic liver disease worldwide.
HBV-infected patients are at a lifetime risk of developing liver cirrhosis and hepatocellular …

Despite decreasing the prevalence of chronic hepatitis B (CHB), it is still a major health care
challenge. Current antiviral regimens aim to suppress hepatitis B virus (HBV) …

Chronic hepatitis B can currently be medically managed with either pegylated interferon-
alpha (pegIFN-α) or one of the five nucleos (t) ide analog Direct Acting Antivirals (DAAs) that …

Several national and international guidelines have been published in the last years focusing
on the problem of how to best treat patients with chronic hepatitis B virus (HBV) infection …

Chronic hepatitis B (CHB) is a worldwide public health problem which represents an
enormous economic and social burden. Convincing evidence has shown that persistent …